Advocate for Change

Advocate for policy

Fighting for more resources and new public policies to improve quality of life for all those affected

Ensuring better patient access to essential health care is critical to the needs of our community. Working alongside regulators and policymakers, we believe education is key to improving the lives of all those affected by brain tumors, and essential for change.

Take action now

TAKE ACTION NOW

Let your voice be heard - join us and take action on critical issues affecting the brain tumor community today.

Advocate tools and training

Advocacy tools

Become more informed about key public policy issues and learn how to educate your elected officials.

Latest news

Latest Public Policy News

Stay up to date on the latest in brain tumor research funding, access to care, and advocacy efforts across the community.

From the Blog

  1. November 25, 2014

    Five Key Updates from the 2014 Scientific Meeting of the Society for Neuro-Oncology

    The Society for Neuro-Oncology (SNO) Annual Scientific Meeting is a multi-day conference that serves as one of the most important gatherings in the field of brain tumor research and drug development. Over three days, presentations are given on some of the most promising research efforts in the field, as well as critical updates on many […]

    Five Key Updates from the 2014 Scientific Meeting of the Society for Neuro-Oncology Read more | 
  2. November 20, 2014

    Guest Blog: Why I want you to join us on Dec. 2

    August 10, 2010, was a Tuesday. I got confirmation that what my mind and body had been telling me for months, was true. I had a brain tumor. It was a gift that I got the care I needed, and am here today. I got involved with the National Brain Tumor Society to connect with […]

    Guest Blog: Why I want you to join us on Dec. 2 Read more | 
  3. November 17, 2014

    Encouraging Results from Novocure Clinical Trial

    Novocure, a company that creates medical devices to treat cancer, announced this weekend that their Novo-TTF-100A system (now being called Optune), in combination with temozolomide (also know as Temodar or TMZ), demonstrated improved survival in newly diagnosed glioblastoma multiforme (GBM) patients in a clinical trial, compared with temozolomide alone. The announcement was made at the […]

    Read more | 
More from the blog